Abstract

Abstract Nephrology is benefited from a growing body of high-quality clinical evidence, including clinical trials of pharmacological therapies and health service research on alternative care approaches. Consequently, there is increasing need to perform economic evaluations in kidney disease, to inform reimbursement decisions and optimise healthcare spending thereby improving patient care within budget constraints. Cost-effectiveness assesses if the additional health gains are worth any additional costs, by estimating differences in the quality and quantity of life, and the costs, from the point of intervention over observed but also longer (even lifetime) horizon, capturing the entire patient pathway through healthcare, for example, from early-stage chronic kidney disease (CKD) through to dialysis or transplantation. Working with stakeholders to define the decision problem, merging evidence from a range of sources including clinical trials complicated by limited follow-up and non-generalisable participants, surrogacy studies to estimate the intervention’s impact estimated glomerular filtration rate (eGFR) and proteinuria have on longer-term kidney failure risk, quality of life data collected ideally using instruments sensitive to kidney disease progression, and other real-world data, are required to make extrapolations sufficiently far into the patient’s lifetime to capture kidney failure. Consideration of disadvantaged populations and how interventions may operate differently in certain groups potentially broadening health inequalities may be indicated. Failure to capture competing risks of cardiovascular disease and death will bias estimates of kidney failure. Application of our tips, combined with an understanding how decision-makers use cost-effectiveness results, combined with information about factors like rarity and disease severity maximises the likelihood of new kidney treatments and care approaches being adopted.

Affiliated Institutions

Related Publications

Publication Info

Year
2025
Type
article
Citations
0
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

0
OpenAlex

Cite This

James Fotheringham, Harry Hill, Olena Mandrik et al. (2025). Ten tips on performing economic evaluation in kidney disease. Clinical Kidney Journal . https://doi.org/10.1093/ckj/sfaf386

Identifiers

DOI
10.1093/ckj/sfaf386